In Vitro: JNJ-38877605 (0.5 μΜ, 24 h) inhibits CPNE1 (HY-P70097)-induced activation of the MET signaling pathway in A549 cells. JNJ-38877605 (JNJ) (5, 10, 20 μΜ, 2, 5, 8 days) inhibits c-Met phosphorylation and results in less lipid accumulation and triglyceride (TG) content with no cytotoxicity in 3T3-L1 cells.
In Vivo: JNJ-38877605 (50 mg/kg, p.o., once daily for 13 days) counteractes radiation-induced invasiveness, promotes apoptosis in tumor xenografts. JNJ-38877605 (40 mg/kg, p.o., once daily for 3 days) decreases in plasma concentration of IL8, GROa, uPAR Met-addicted GTL16 xenografts mice model.